Arena doses first subject in ELEVATE UC 12 phase 3 trial of Etrasimod in ulcerative colitis

This article was originally published here

ELEVATE UC 12 is the second of two pivotal trials within the Phase 3 ELEVATE UC registrational program to assess the safety and efficacy of etrasimod 2 mg.

The post Arena doses first subject in ELEVATE UC 12 phase 3 trial of Etrasimod in ulcerative colitis appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply